TD Asset Management
ZNTL icon

TD Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

TD Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-106,080
Closed -$321K – 1281
2024
Q4 		$321K Hold
106,080
– – ﹤0.01% 1206
2024
Q3 		$398K Buy
106,080
+3,200
+3% +$11.6K ﹤0.01% 1324
2024
Q2 		$421K Sell
102,880
-155,938
-60% -$1.74M ﹤0.01% 1295
2024
Q1 		$4.08M Buy
258,818
+68,650
+36% +$944K ﹤0.01% 819
2023
Q4 		$2.88M Buy
190,168
+9,400
+5% +$137K ﹤0.01% 890
2023
Q3 		$3.63M Buy
180,768
+78,140
+76% +$1.98M ﹤0.01% 801
2023
Q2 		$2.9M Buy
102,628
+19,921
+24% +$478K ﹤0.01% 863
2023
Q1 		$1.42M Hold
82,707
– – ﹤0.01% 1070
2022
Q4 		$1.67M Hold
82,707
– – ﹤0.01% 1038
2022
Q3 		$1.78M Buy
82,707
+100
+0.1% +$2.73K ﹤0.01% 1039
2022
Q2 		$2.32M Sell
82,607
-23,296
-22% -$617K ﹤0.01% 967
2022
Q1 		$4.89M Sell
105,903
-11,730
-10% -$633K ﹤0.01% 830
2021
Q4 		$9.89M Buy
117,633
+26,375
+29% +$2.04M 0.01% 684
2021
Q3 		$6.08M Buy
91,258
+9,292
+11% +$536K 0.01% 776
2021
Q2 		$4.36M Buy
81,966
+52,751
+181% +$2.83M ﹤0.01% 864
2021
Q1 		$1.27M Buy
29,215
+4,722
+19% +$203K ﹤0.01% 1219
2020
Q4 		$1.27M Buy
24,493
+2,000
+9% +$90.2K ﹤0.01% 1125
2020
Q3 		$735K Hold
22,493
– – ﹤0.01% 1148
2020
Q2 		$1.08M Buy
+22,493
New +$863K ﹤0.01% 1041

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TD Asset Management's ZNTL Position: Q1 2025 in Review

TD Asset Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2025, closing a stake of 106,080 shares — an estimated $321K sold.

TD Asset Management first reported a position in ZNTL in Q2 2020 and held it in 19 quarters. The position peaked at $9.89M in Q4 2021. 132 funds tracked by Wall St. Rank hold ZNTL as of Q1 2025.

  • TD Asset Management reported no remaining Zentalis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • TD Asset Management sold 106,080 Zentalis Pharmaceuticals shares in Q1 2025, an estimated $321K.
  • TD Asset Management first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 19 quarters.
  • TD Asset Management's Zentalis Pharmaceuticals position peaked at $9.89M in Q4 2021.
  • 132 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2025.

Based on TD Asset Management's 13F filing for Q1 2025, filed 7 May 2025.